Glycopyrrolate topical - Dermira

Drug Profile

Glycopyrrolate topical - Dermira

Alternative Names: DRM-04B; DRM04; Glycopyrronium tosylate; Glycopyrronium tosylate hydrate; Glycopyrronium tosylate monohydrate

Latest Information Update: 21 Sep 2016

Price : $50

At a glance

  • Originator Dermira
  • Class Antiasthmatics; Antispasmodics; Pyrrolidines; Quaternary ammonium compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Hyperhidrosis

Most Recent Events

  • 20 Sep 2016 Glycopyrrolate topical licensed to Maruho in Japan
  • 20 Sep 2016 Maruho plans a phase I trial for Hyperhidrosis in Japan
  • 01 Jun 2016 Efficacy and adverse events data from the phase III ATMOS-1 and ATMOS-2 trials in Hyperhidrosis released by Dermira
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top